StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) in a research report report published on Monday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.
Shares of TTNP stock opened at $0.88 on Monday. Titan Pharmaceuticals has a 12 month low of $0.85 and a 12 month high of $3.10. The company has a 50 day simple moving average of $1.02 and a two-hundred day simple moving average of $1.27.
A hedge fund recently raised its stake in Titan Pharmaceuticals stock. Morgan Stanley lifted its position in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Rating) by 1,058,500.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 158,790 shares of the specialty pharmaceutical company’s stock after purchasing an additional 158,775 shares during the period. Morgan Stanley owned about 1.61% of Titan Pharmaceuticals worth $413,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 17.59% of the stock is currently owned by institutional investors.
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.
- Get a free copy of the StockNews.com research report on Titan Pharmaceuticals (TTNP)
- 3 Tech Stocks to Buy for Retirement
- Schlumberger Analyst Coverage Drives Market Higher
- Poor Timing Will Put Delta Air Lines on Standby For Risk-Off Investors
- Simply Good Foods Stock is a Healthy Defensive Play
- 3 Stocks Down Big in ’22 That Are Worth Buying
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.